Say HRT in most rooms and someone will say cancer. The NHS website says older studies made many people wary of HRT, and that their view is now out of date because it weighed the risks without the benefits. Here is what the guidance says today, both sides.
HRT risks and benefits
Most of what families say about HRT comes from studies the NHS now calls out of date. What the current guidance says about the benefits and the risks, and the questions that turn them into a decision about you.
The words and the guidance
- English
- HRT risks and benefits
- Also searched as
- HRT side effects, HRT safety, is HRT safe, HRT and breast cancer, MHT risks
- Urdu
- HRT کے فائدے اور خطرے
- Roman Urdu
- HRT ke faide aur khatre
- The NHS website says the benefits of HRT usually outweigh the risks, and that for women under 60 with menopause symptoms who are not at high risk of breast cancer or blood clots, the benefits are likely to outweigh the risks.
- NICE NG23 asks doctors to tailor the benefits and risks to your age, circumstances and risk factors, using NICE's discussion aid on HRT, which shows how many women in every thousand develop each condition with and without it (1.4.2, 1.6.2).
- The British Menopause Society's fast facts on breast cancer say that in women at low underlying risk, which is most women, the symptom benefits of HRT for up to five years outweigh the potential harm.
- The Pakistan Menopause Society's 2026 recommendations say the balance of benefit and risk is most favourable when HRT starts before 60 or within 10 years of the menopause (section 5.12).
What it is
With HRT, benefits and risks both depend on the same handful of things: your age, whether it is combined or estrogen-only, whether it goes through the skin or comes as a tablet, how long you take it, and your own history. NICE NG23 asks doctors to tailor the conversation to exactly those (1.4.2).
This page is the map. The sums for you get done with your doctor, ideally with NICE's discussion aid on the desk.
What the guidance lists
The benefits
The NHS website lists relief from hot flushes, night sweats, sleep problems, anxiety and low mood caused by the menopause, and vaginal dryness. It also says HRT helps prevent osteoporosis, the bone thinning that follows the fall in estrogen, and helps keep muscles strong. NICE NG23 says fracture risk falls while you take HRT and the benefit fades once you stop. See bone health.
Breast cancer
This is the big one, so the exact words matter. NICE NG23 says breast cancer risk rises with combined HRT, more the longer it is taken, and falls after stopping, though some raised risk persists for at least 10 years. It adds: "There is a very small increase in risk of death from breast cancer with combined HRT." With estrogen-only HRT, NICE says there is very little or no increase.
The British Menopause Society's January 2026 tool for clinicians notes that a relative with breast cancer may raise your own background risk but is not by itself a reason HRT is ruled out. More in breast health.
Blood clots and stroke
NICE NG23 is plain on clots: "VTE risk is not increased with transdermal HRT." And: "VTE risk is greater with oral than transdermal HRT." Transdermal means through the skin; VTE means a blood clot in a vein.
On stroke, NICE says HRT tablets raise the risk, more so with higher doses, longer use and an older starting age, while estrogen through the skin is unlikely to raise it.
Heart, diabetes and the womb
"Coronary heart disease risk does not increase with combined HRT," says NICE NG23, and "The risk of developing type 2 diabetes does not increase with HRT." NICE also says HRT should not be offered to prevent heart disease or dementia, and that overall it is unlikely to change life expectancy.
For South Asian women this section matters more. The BMS notes higher rates of insulin resistance, diabetes, central weight gain and high blood pressure in South Asian women around the menopause. See heart health and diabetes risk.
With a womb, estrogen on its own raises the risk of womb cancer, which is why a progestogen is added (NICE NG23).
Gallbladder
The Menopause Society, in the US, says HRT raises the risk of gallstones and rates that evidence as strong. Observational studies suggest less risk through the skin than with tablets, not yet confirmed in trials.
What the guidelines say about treatment
NICE NG23 asks doctors to discuss the benefits and risks of every option, not just HRT (1.4.1). On when to start, The Menopause Society agrees with the PMS that before 60 or within 10 years of the menopause is best, and rates that evidence as strong. Starting after 60 is not ruled out, it says, but needs careful weighing of your own benefits and risks.
The PMS recommendations say there should be no fixed limit on how long HRT is taken: carrying on is decided jointly by you and your doctor, looking at your goals and your benefits and risks at each review (section 5.14). The European Menopause and Andropause Society (EMAS) and The Menopause Society agree, and EMAS says stopping routinely at 65 is not recommended.
If the balance does not work for you, the guidelines list non-hormonal treatments.
When to see a doctor
If you are worried about the risks, whether you are thinking of starting or already taking HRT, the NHS website says to speak to a doctor. Bring your family history of breast cancer, blood clots, heart disease and stroke.
While you take HRT, the NHS website asks you to keep going to breast screening, and lists the signs to act on: a new breast lump, pain or swelling in one calf, or unexpected bleeding needs a doctor. Chest pain with breathlessness needs emergency help.
Questions to ask your doctor
- Given my age and my health, do the benefits of HRT outweigh the risks for me?
- Can we look at NICE's discussion aid on HRT together?
- My mother or sister had breast cancer. How does that change things?
- I have diabetes or high blood pressure. Does that change the type you would suggest?
Faith and family
The BMS notes that in many communities the menopause is seen as natural, and some women hesitate to use medicine for something natural. Some ask whether easing it with medicine sits right with their faith. That question deserves a qualified scholar, not a guess.
At home, the fear often arrives secondhand. You do not have to win that argument at the dinner table. Take the questions above to your doctor and bring the answers home.
Track it
- Roshara's symptom score rates 27 symptoms in a few minutes, with no account. The total is something to take to your appointment. Take the symptom score
- Where am I? names the stage you might be in. Six questions. Take Where am I?
- Log it day by day in the tracker, with what came just before. It needs a free account. Open the tracker
Common questions
- Does HRT cause breast cancer?
- The British Menopause Society's fast facts say most women will not be diagnosed with breast cancer as a result of taking HRT. Estrogen-only HRT shows little or no change in risk; combined HRT can carry a small increase that grows the longer it is taken. (Source: British Menopause Society, Tool for Clinicians: Fast facts, HRT and breast cancer risk (updated September 2025))
- Is HRT safe if I have diabetes?
- NICE NG23 says the risk of developing type 2 diabetes does not increase with HRT, and recommends considering HRT for women with type 2 diabetes once other conditions have been taken into account, with specialist advice if needed (1.5.27). (Source: NICE NG23, Menopause: identification and management (last updated 15 April 2026))
- My menopause came before 40 and I started HRT young. Do those years count against my breast risk?
- The British Menopause Society's fast facts say that with premature ovarian insufficiency, menopause before 40, years on HRT are counted from the age of 50, not from when you started. EMAS says the same. (Source: British Menopause Society, Tool for Clinicians: Fast facts, HRT and breast cancer risk (updated September 2025))
Sources
- NHS website, Benefits and risks of hormone replacement therapy (HRT) (reviewed 8 February 2023)Section: Benefits of HRT; Risks of HRT · Opened 1 October 2026
- NICE NG23, Menopause: identification and management (last updated 15 April 2026)Section: 1.4.1; 1.4.2; 1.5.27; 1.6.1 to 1.6.5, tables 1 and 2 · Opened 1 October 2026© NICE 2026 Menopause: identification and management. Available from www.nice.org.uk/guidance/ng23 All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
- British Menopause Society, Tool for Clinicians: Fast facts, HRT and breast cancer risk (updated September 2025)Section: HRT and the risk of being diagnosed with breast cancer; HRT and women at increased risk · Opened 1 October 2026
- NHS website, Side effects of oestrogen tablets, patches, gel and spray (reviewed 5 January 2023, review was due 5 January 2026)Section: Serious side effects · Opened 1 October 2026
- British Menopause Society, Tool for Clinicians: What is the menopause? (reviewed January 2026)Section: What is the risk of breast cancer with HRT? · Opened 1 October 2026
- British Menopause Society, Tool for Clinicians: Menopause in ethnic minority women (published June 2023, review was due June 2026)Section: Barriers to seeking help; South Asian women · Opened 1 October 2026
- Pakistan Menopause Society, Good Clinical Practice Recommendations for Menopause Care in Pakistan (JSOGP 16(2), 28 April 2026)Section: 5.12; 5.14 · Opened 1 October 2026
- The Menopause Society (then The North American Menopause Society), The 2022 hormone therapy position statement, Menopause 2022;29(7):767-794Section: Gallbladder and liver; Duration of use, initiation after age 60 years, and discontinuation of hormone therapy (key points) · Opened 15 October 2026
- European Menopause and Andropause Society, Menopause Essentials 2026: Starting and stopping treatment (July 2026)Section: Duration of MHT use · Opened 15 October 2026
- European Menopause and Andropause Society, Menopause Essentials 2026: Risk of breast cancer (July 2026)Section: MHT and breast cancer risk · Opened 15 October 2026